ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO987

KETO-ADPKD: A Randomized, Controlled Trial on Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic

Authors

  • Cukoski, Sadrija, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Lindemann, Christoph Heinrich, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Brecht, Theresa, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Kühn, Adrian, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Arjune, Sita, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Todorova, Polina, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Meyer, Franziska Inka, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Siedek, Florian, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Antczak, Philipp, Universitat zu Koln, Cologne, Nordrhein-Westfalen, Germany
  • Gottschalk, Ingo, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Weimbs, Thomas, University of California Santa Barbara, Santa Barbara, California, United States
  • Grundmann, Franziska, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
  • Mueller, Roman-Ulrich, Uniklinik Koln, Cologne, Nordrhein-Westfalen, Germany
Background

ADPKD animal models revealed a potent beneficial effect of ketogenic dietary interventions (KDIs).

Methods

63 ADPKD patients were randomized to 3 months of ketogenic diet (KD), monthly 3-day water fasting (WF) or ad libitum diet (Control). The primary endpoint was a feasibility analysis combining a questionnaire and metabolic efficacy (blood β-Hydroxybutyric acid (BHB), breath acetone), to be reached by ≥75% in each group. Total kidney volume (TKV) and total liver volume (TLV) were quantified among secondary endpoints using MRI at baseline (BL) and end-of-treatment (EOT). Safety analyses focused on uric acid levels and hepatic/renal complications.

Results

The primary feasibility endpoint was reached for the WF (80%) but not the KD (43%) group. The lower percentage (KD) was driven by the pre-defined BHB threshold (≥0.8 mmol/l at all visits). 18/23 KD patients showed higher BHB levels at all on-diet visits compared to BL. Mean ΔhtTKV from BL to EOT was: Control +13.9ml/m±28.8, WF +7.1±47.2, KD -12.8±61.2; ANOVA vs. Control: p KD=0.08, WF=0.67. Mean ΔhtTLV from BL to EOT was: Control +42.2ml/m±166.0, WF -10.0±98.2, KD -55.1±72.5, with a statistically significant difference between KD and Control (p KD=0.01, WF=0.17). 2 patients experienced symptomatic kidney stones in KD. At EOT, uric acid levels > ULN were detected in 3 Control, 6 KD and 4 WF patients. Only 1 patient (Control) showed a mild ALT elevation (<1.5xULN). No cases of AST > ULN (EOT) or creatinine increase ≥50% from BL to EOT were recorded. eGFR increased in KD and WF (BL to EOT; KD 5.04ml/min±9.45, WF 0.21±5.12) while decreasing in the Control (-1.26±9.48). This difference was statistically significant comparing KD to Control (p KD=0.01, WF=0.5).

Conclusion

Both KDIs induced ketogenesis and were rated as feasible by patients, also when asked about long-term feasibility. KD did not reach the combined primary feasibility endpoint based on a predefined BHB threshold, but nearly all KD patients showed increased BHB at all visits. The impact of KD on TLV/TKV and eGFR is of special interest. Regarding safety, the formation of kidney stones will need specific attention.

Funding

  • Other NIH Support